Navigation Links
Mettler-Toledo International Inc. Reports Second Quarter 2013 Results
Date:7/25/2013

despite the challenging environment.  Execution of our strategic initiatives will continue to be a key factor in gaining share and driving further earnings growth."Other MattersThe Company will host a conference call to discuss its quarterly results today (Thursday, July 25) at 5:00 p.m. Eastern Time.  To hear a live webcast or replay of the call, visit the investor relations page on the Company's website at www.mt.com/investors.  The presentation referenced in the conference call will be located on the website prior to the call.

METTLER TOLEDO is a leading global supplier of precision instruments and services. The Company has strong leadership positions in all businesses and believes it holds global number-one market positions in a majority of them. Specifically, METTLER TOLEDO is the largest provider of weighing instruments for use in laboratory, industrial and food retailing applications. The Company is also a leading provider in analytical instruments for use in life science, reaction engineering and real-time analytic systems used in drug and chemical compound development and process analytics instruments used for in-line measurement in production processes. In addition, METTLER TOLEDO is the largest supplier of end-of-line inspection systems used in production and packaging for food, pharmaceutical and other industries. Additional information about METTLER TOLEDO can be found at www.mt.com/investors.

Statements in this press release which are not historical facts constitute "forward-looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934.  These statements involve known and unknown risks, uncertainties and other factors that may cause our or our businesses' actual results, levels of activity, performance or achievements to be materially different from
'/>"/>

SOURCE Mettler-Toledo International Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
6. Chindex International, Inc. to Report First Quarter 2012 Financial Results
7. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
8. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
9. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
10. Bacterin International Signs Its Third National GPO Contract with Novation
11. SurgLine International, Inc. Chief Executive Officer, Thomas Toland, Exclusive Interview on Stock Traders Talk Radio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 2012  JARVIK HEART, Inc., a privately-held company that develops ... of its Pivotal Trial for evaluation of the Jarvik ... device for DT means that it will provide long-term, ... are not candidates for heart transplant. The approval permits ...
... Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, announced today its ... full year ended December 31, 2011. ... Fourth quarter net revenue increased 25.2% year-over-year ...
Cached Medicine Technology:JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 2JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 3Mindray Announces 2011 Fourth Quarter and Full Year Results 2Mindray Announces 2011 Fourth Quarter and Full Year Results 3Mindray Announces 2011 Fourth Quarter and Full Year Results 4Mindray Announces 2011 Fourth Quarter and Full Year Results 5Mindray Announces 2011 Fourth Quarter and Full Year Results 6Mindray Announces 2011 Fourth Quarter and Full Year Results 7Mindray Announces 2011 Fourth Quarter and Full Year Results 8Mindray Announces 2011 Fourth Quarter and Full Year Results 9Mindray Announces 2011 Fourth Quarter and Full Year Results 10Mindray Announces 2011 Fourth Quarter and Full Year Results 11Mindray Announces 2011 Fourth Quarter and Full Year Results 12Mindray Announces 2011 Fourth Quarter and Full Year Results 13Mindray Announces 2011 Fourth Quarter and Full Year Results 14Mindray Announces 2011 Fourth Quarter and Full Year Results 15Mindray Announces 2011 Fourth Quarter and Full Year Results 16Mindray Announces 2011 Fourth Quarter and Full Year Results 17
(Date:4/24/2014)... often coexist with the negative and stressful outcomes for ... diagnosed with a life-limiting illness, says a recent study ... , While the challenges are numerous and life-changing and ... participated in the Waterloo-led research reported positive outcomes as ... appear in the most recent issue of the ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... say clinical trials for a new experimental drug ... promising. Patients treated with CPX-351, a combination of ... better responses than patients treated with the standard ... leukemia is an aggressive blood cancer with very ... patients," explained Jeffrey Lancet, M.D., senior member of ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... LANSING, Mich. To tackle the growing number of psychiatric cases ... team of Michigan State University doctors from the colleges of ... from across the state via video conference. , On ... see up to 10 patients each from as far away ...
... study says , , MONDAY, Oct. 27 (HealthDay News) -- ... coronary conditions, might reduce the effect of the clot-preventing ... blockers appear to inactivate an enzyme essential for the ... published online Oct. 28 in the Journal of ...
... Treatment, ST. LOUIS, Oct. 27 Leading ... deliver radioactive seed therapy,in the prostate. The innovative ... the prostate during procedures. With the gland stabilized,physicians ... to map,and confirm placement of radiation., Unveiled ...
... Study found desires remained essentially unchanged over 3-year period ... declines in either mental or physical health, most senior ... want their end-of-life care to be when the time ... that despite observing an overall stability in patient perspective, ...
... Oct. 27 SpectraCell Laboratories, Inc.,announced that ... facilities. Recently,SpectraCell occupied a 20,000 sq. ft. ... 2005. The planned expansion added a second ... campus. The new $3.5 million facility houses,SpectraCell,s ...
... an initial,step in the creation of a wellness ... it has acquired HealthMedia, Inc., a,privately held company ... change interventions. Terms of the transaction were not,disclosed., ... to,effectively emulate a health coach via the web. ...
Cached Medicine News:Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 2Health News:Seniors Tend to Stick With End-of-Life Care Preferences 3Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: